Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15957272 | 1.00 | CA1 (0.32) | CA1CA2CA4ESR2KMT2A | |
| Ethylene SCHEMBL3215921 | 0.94 | — | — | |
| SCHEMBL4611126 | 0.81 | CA1 (0.40) | CA1CA2CA4KMT2A | |
| SCHEMBL8569287 | 0.79 | CA1 (0.44) | CA1CA2CA4KMT2A | |
| SCHEMBL13255133 | 0.77 | — | — | |
| SCHEMBL19807604 | 0.77 | — | — | |
| SCHEMBL1266170 | 0.77 | — | — | |
| SCHEMBL8206110 | 0.75 | — | — | |
| SCHEMBL125652 | 0.73 | — | — | |
| SCHEMBL5242956 | 0.73 | CA1 (0.30) | CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-01-18 | — | — | US | disclosed |
| CN-114401952-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114195787-A | 2-nitro-2-azaadamantane-4, 6, 8-triol trinitrate and preparation method thereof | 南京理工大学 | 2022-03-18 | — | — | CN | disclosed |
| EP-3962899-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-11267786-B2 | [3.3.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-11-25 | — | — | US | disclosed |
| US-20210214308-A1 | NOVEL [3.3.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210214308-A1 | NOVEL [3.3.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-07-15 | — | — | US | disclosed |
| US-8710077-B2 | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-04-29 | — | — | US | disclosed |
| EP-2102164-B1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI AVENTIS (FR) | 2010-12-01 | — | — | EP | disclosed |
| US-20100056553-A1 | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| EP-2102164-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008130721-A1 | PREPARATION OF SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008089010-A1 | PREPARATION OF SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008077556-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| US-5292959-A | 4,4-dinitroadamantange-2,6-dione | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1994-03-08 | — | — | US | disclosed |
| US-5202508-A | Composition | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1993-04-13 | — | — | US | disclosed |
| US-5180853-A | 4,4-6,6-tetronitroadamantan-2-one | DAVE PARITOSH R (US) | 1993-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214308-A1 | NOVEL [3.3.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, KYNU | CA1 1148/4885CA2 1337/4885CA4 1684/4885 |
| US-20210363136-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | CA1 4873/4885CA2 4710/4885CA4 4856/4885 |
| US-20240018133-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | CA1 4873/4885CA2 4710/4885CA4 4856/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | CA1 4872/4885CA2 4701/4885CA4 4859/4885 |
| US-11267786-B2 | [3.3.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, KYNU | CA1 1382/4885CA2 1741/4885CA4 2354/4885 |
| US-20100056553-A1 | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | CA1 4496/4885CA2 1743/4885CA4 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.